In summary, the present systematic review of published RCTs suggested that FC reduces serum phosphate, i-PTH, and FGF-23 levels and improves anemia-related parameters, namely Hb, TSAT, and ferritin in patients with CKD stage 3–5D. Here, GSTM1 is linked to chronic kidney disease.